A chronic myeloid leukemia case with two ischemic cerebrovascular attacks during nilotinib therapy

Year 2017, Volume: 42 Issue: 3, 602 - 603, 30.09.2017

Gül İlhan

https://doi.org/10.17826/cutf.324597

Abstract

A chronic myeloid leukemia case with two ischemic cerebrovascular attacks during nilotinib therapy

Keywords

nilotinib, cerebrovascular event

Nilotinib tedavisi sırasında iki kez iskemik serebrovasküler atak geçiren bir kronik miyeloid lösemi olgusu

Abstract

Nilotinib tedavisi sırasında iki kez iskemik serebrovasküler atak geçiren bir kronik miyeloid lösemi olgusu

Keywords

nilotinib, serebrovasküler olay

References

• 1. Jager NG, Stuurman FE, Baars JW, Opdam FL. Cerebrovascular events during nilotinib treatment. Neth J Med. 2014;72:113-4.
• 2. Larson RA, Kim DW, Joatar S. ENESTnd 5-year update: Long term outcomes pf patients with chronic myeloid leukemia in chronic phase (CM-CP) treated with frontline nilotinib (NIL) versus imatinib (IM): . J Clin Oncol. 2014;32:7073.
• 3. Jabbour E, Kantarjian H, Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252-65.
• 4. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610-1.
• 5. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9.
• 6. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337-40.